TherapeuticsMD Inc (TXMD)

6.13
AMEX : Health Care
Prev Close 5.90
Day Low/High 5.88 / 6.17
52 Wk Low/High 4.39 / 11.26
Avg Volume 2.27M
Exchange AMEX
Shares Outstanding 196.58M
Market Cap 1.16B
EPS -0.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Jim Cramer's 'Mad Money' Recap: This Rotation's Too Hard for the Bulls

Jim Cramer's 'Mad Money' Recap: This Rotation's Too Hard for the Bulls

Cramer wonders if this market has gotten too enthusiastic for the Trump agenda.

TherapeuticsMD's Weakness Is an Opportunity

Our research suggests the risk/reward potential is attractive at current levels.

Bullish and Bearish Reversals in the Market

Bullish and Bearish Reversals in the Market

Charts showing up or down trends in the past week.

Analysts Like 3 Portfolio Names

Builders FirstSource, Huntington Bancshares and TherapeuticsMD all received upbeat outlooks from analysts overnight.

January 2017 Options Now Available For TherapeuticsMD (TXMD)

January 2017 Options Now Available For TherapeuticsMD (TXMD)

Investors in TherapeuticsMD, Inc. saw new options begin trading today, for the January 2017 expiration.

Stocks Under $10 Weekly Summary

We booked some profits in Synovus Financial and used part of the proceeds to buy more Yamana Gold.

Stocks Under $10 Weekly Summary

We sold the rest of our Datalink holdings and will use the proceeds to add a name to our portfolio.

TherapeuticsMD To Present At Two Upcoming Investor Conferences

TherapeuticsMD To Present At Two Upcoming Investor Conferences

TherapeuticsMD, Inc. (NYSE MKT:TXMD), an innovative women's healthcare company, today announced that the company will participate in the Stifel 2016 Annual Healthcare Conference on November 15, and the Jefferies 2016 London...

TherapeuticsMD Expands Commercial And Business Development Leadership

TherapeuticsMD Expands Commercial And Business Development Leadership

TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced two new strategic hires: Dawn Halkuff as Chief Commercial Officer and Yulii Bogatyrenko as Senior Vice President of Business...

TherapeuticsMD Announces Third Quarter 2016 Financial Results

TherapeuticsMD Announces Third Quarter 2016 Financial Results

TherapeuticsMD, Inc. (NYSE MKT:TXMD), an innovative women's healthcare company, today announced its third quarter financial results for the quarter ended September 30, 2016.

Stocks Under $10 Portfolio: Tax-Loss Selling Weighs on Indices

Stocks Under $10 Portfolio: Tax-Loss Selling Weighs on Indices

We used this week's declines to add to our positions in Teligent, Builders FirstSource and Sonus Networks.

June 2017 Options Now Available For TherapeuticsMD (TXMD)

June 2017 Options Now Available For TherapeuticsMD (TXMD)

Investors in TherapeuticsMD, Inc. saw new options begin trading today, for the June 2017 expiration.

TherapeuticsMD To Host Third Quarter Financial Results Conference Call And Webcast On November 3

TherapeuticsMD To Host Third Quarter Financial Results Conference Call And Webcast On November 3

TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced that it will host a conference call and live audio webcast to discuss third quarter financial and business results on...

Adding to 2 Positions

We're buying more Builders FirstSource and TherapeuticsMD in a market that is starting the day lower.

Stocks Under $10 Weekly Summary

We used this week's selloff to take positions in a student loan provider and a generic drug maker.

Rebound May Be in Store for Beaten-Down Shares of TherapeuticsMD

Rebound May Be in Store for Beaten-Down Shares of TherapeuticsMD

Although many biotechnology stocks have fallen this year due to disappointing clinical trial results, what is the deal with this stock that is down precipitously despite encouraging R&D news?

Stocks Under $10 Weekly Summary

September jobs data weighed on indices, while we booked profits in ON Semiconductor and rolled some funds into Yamana Gold.

Stocks Under $10 Weekly Summary

We made several moves in the portfolio during a volatile week, and a slew of economic reports next week could keep the market on edge.

Stocks Under $10 Weekly Summary

U.S. stocks close out week with a modest gain.

TherapeuticsMD Announces Multiple Presentations Related To Yuvvexy™ (TX-004HR) At Two Upcoming Medical Conferences

TherapeuticsMD Announces Multiple Presentations Related To Yuvvexy™ (TX-004HR) At Two Upcoming Medical Conferences

TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced the schedule of nine posters and oral presentations at upcoming medical conferences related to Yuvvexy, the...

Picking Up More TherapeuticsMD

The company is less than 48 hours removed from the latest milestone in its product pipeline, so we'll buy on weakness.

TherapeuticsMD Gains FDA Application Nod

The application is for Yuvvexy, a biosimilar hormone treatment for vulvar and vaginal atrophy.

TherapeuticsMD Announces FDA Acceptance Of New Drug Application (NDA) And Prescription Drug User Fee Act (PDUFA) Date For Yuvvexy™ (TX-004HR)

TherapeuticsMD Announces FDA Acceptance Of New Drug Application (NDA) And Prescription Drug User Fee Act (PDUFA) Date For Yuvvexy™ (TX-004HR)

TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced the acceptance of the NDA for Yuvvexy, the conditionally-approved trade name for TX-004HR, by the U.

Stocks Under $10 Weekly Summary

We continue to screen new names amid a week of volatility in the broader market.

Novavax's Steep Decline Underlines Small-Cap Biotech Risk

But we remain committed to our position in TherapeuticsMD.

Stocks Under $10 Weekly Summary

We added one new name to the Bullpen during a holiday-shortened week that ended with the worst daily decline since late June.

Stocks Under $10 Portfolio: Not Resting on Our Laurels

Stocks Under $10 Portfolio: Not Resting on Our Laurels

The portfolio has outperformed the Russell 2000 index by more than 400 basis points, year to date.

Stocks Under $10 Weekly Summary

We added to two portfolio positions this week and also used market strength to book some profits.